Top

Published in:

01-09-2011 | Movement Disorders - Short Communication

Elevation of total homocysteine levels in patients with Parkinson’s disease treated with duodenal levodopa/carbidopa gel

Authors: Thomas Müller, Constanze Jugel, Reinhard Ehret, Georg Ebersbach, Gunar Bengel, Siegfried Muhlack, Fabian Klostermann

Published in: Journal of Neural Transmission | Issue 9/2011

Abstract

Levodopa/carbidopa (LD/CD) application elevates total plasma homocysteine (thcys). We determined thcys-, LD- and 3-O-methyldopa (3-OMD) concentrations in 28 patients with Parkinson’s disease (PD) on a LD/CD duodenal gel treatment. We found a distinct thcys increase (29.52 ± 28.98 μmol/l [median ± SD]) above the 15 μmol/l threshold and a significant (R = 0.7) correlation between LD and 3-OMD. thcys ascent was observed in relation with the onset of atherosclerosis, non-motor symptoms and polyneuropathy in PD patients in the long term.

Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR (2010) Levodopa and 3-OMD levels in Parkinson patients treated with duodopa. Eur Neuropsychopharmacol 20:683–687PubMedCrossRef

Benetello P, Furlanut M, Fortunato M, Pea F, Baraldo M (1997) Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa–carbidopa association. Pharmacol Res 35:313–315PubMedCrossRef

Chandra G, Gangopadhyay PK, Senthil Kumar KS, Mohanakumar KP (2006) Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague–Dawley rats. Brain Res 1075:81–92PubMedCrossRef

Furukawa Y, Tomioka N, Sato W, Satoyoshi E, Hayashi K, Furukawa S (1989) Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett 247:463–467PubMedCrossRef

Hortin GL, Seam N, Hoehn GT (2006) Bound homocysteine, cysteine, and cysteinylglycine distribution between albumin and globulins. Clin Chem 52:2258–2264PubMedCrossRef

Imamura K, Takeshima T, Nakaso K, Nakashima K (2007) Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. Neuroreport 18:1319–1322PubMedCrossRef

Lee ES, Chen H, Soliman KF, Charlton CG (2005) Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26:361–371PubMedCrossRef

Manca D, Cossu G, Murgia D, Molari A, Ferrigno P, Marcia E, Melis M (2009) Reversible encephalopathy and axonal neuropathy in Parkinson’s disease during duodopa therapy. Mov Disord 24:2293–2294PubMedCrossRef

Meiler B, Andrich J, Müller T (2008) Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 23:145–146PubMedCrossRef

Müller T (2008) Role of homocysteine in the treatment of Parkinson’s disease. Expert Rev Neurother 8:957–967PubMedCrossRef

Müller T (2010) Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-l-methionine and related mechanisms. Int Rev Neurobiol 95:49–71PubMedCrossRef

Müller T, Kuhn W (2006) Tolcapone decreases plasma levels of S-adenosyl-l-homocysteine and homocysteine in treated Parkinson’s disease patients. Eur J Clin Pharmacol 62:447–450PubMedCrossRef

Müller T, Kuhn W (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson’s disease. Mov Disord 24:1339–1343PubMedCrossRef

Müller T, Muhlack S (2010) Acute homocysteine rise after repeated levodopa application in patients with Parkinson’s disease. Parkinsonism Relat Disord 16:688–689PubMedCrossRef

Müller T, Renger K, Kuhn W (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61:657–660PubMedCrossRef

Müller T, Lang UE, Muhlack S, Welnic J, Hellweg R (2005) Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease. Clin Neuropharmacol 28:238–240PubMedCrossRef

Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. J Neural Transm 113:1441–1448PubMedCrossRef

Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216–223PubMedCrossRef

O’Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, az-Arrastia R (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61:865–868PubMedCrossRef

Onofrj M, Bonanni L, Cossu G, Manca D, Stocchi F, Thomas A (2009) Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during l-dopa gel treatment. Parkinsonism Relat Disord 15(Suppl 3): S233–S236

Rogers JD, Sanchez-Saffon A, Frol AB, az-Arrastia R (2003) Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60:59–64PubMedCrossRef

Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D (2008) Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord 23:1850–1859PubMedCrossRef

Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, Wiebe S, Zochodne DW, Suchowersky O (2010a) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68:28–36PubMedCrossRef

Toth C, Suchowersky O, Zochodne D (2010b) Reply: neuropathy as a potential complication of levodopa use in Parkinson’s disease: a pharmacological and pharmacovigilance point of view. Mov Disord 25:525PubMedCrossRef

Zhao WQ, Williams Z, Shepherd KR, Reuben JS, Lee ES, rling-Reed S, Lamango N, Soliman KF, Charlton CG (2002) S-adenosyl-methionine-induced apoptosis in PC12 cells. J Neurosci Res 69:519–529PubMedCrossRef

Title: Elevation of total homocysteine levels in patients with Parkinson’s disease treated with duodenal levodopa/carbidopa gel
Authors: Thomas Müller
Constanze Jugel
Reinhard Ehret
Georg Ebersbach
Gunar Bengel
Siegfried Muhlack
Fabian Klostermann
Publication date: 01-09-2011
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 9/2011
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-011-0614-9

At a glance: The STEP trials

Springer Medicine

Elevation of total homocysteine levels in patients with Parkinson’s disease treated with duodenal levodopa/carbidopa gel

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2011

Family-based association analysis of alcohol dependence in the COGA sample and replication in the Australian twin-family study

Exercise inhibits neuronal apoptosis and improves cerebral function following rat traumatic brain injury

Cognitive function and cholinergic transmission in patients with subcortical vascular dementia and microbleeds: a TMS study

Negative argument for debate with V. O. Emery for J Neural Transmission

AD: Are we intervening too late?

Rare brain biopsy findings in a first ADEM-like event of pediatric MS: histopathologic, neuroradiologic and clinical features